1. Standard of care -Reperfusion therapy: SETMI patients within 12 hours after symptoms onset were included for this study and they should be treated with reperfusion therapy (fibrinolytics or primary PCI). However, ~60% of study patients got reperfusion therapy and the remaining patients departed from standard of care.
-Medications: Only small number of patients took standard medications: clopidogrel (<30%), beta-blockers (<70%), and statins (~70%) The authors' findings may not be generalized to patients with STEMI undergoing reperfusion therapy and standard medications. 2. Inclusion criteria: It is unclear why the authors excluded patients with admission SBP < 100mmHg. 3. Definitions: Bleeding definition is less unclear. The author had better use BARC definition to define bleeding complications. 4. Lack of data: It is well demonstrated that LV function (ejection fraction) and the extent and severity of residual coronary artery disease are two major determinants of prognosis after STEMI. The authors failed to show two key predictors of prognosis
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name lazzeri chiara Institution and Country intensive cardiac care unit heart and vessel deparment Azienda Ospedaliero-Universitaria Careggi Florence Italy Please state any competing interests or state 'None declared': none declared Major issues the Authors should clearly state whether this sentence "It is plausible that elevated admission blood pressure in patients with ACS may restrict adoption of some prognostic significant strategies in clinical practice such as thrombolysis treatment, for fear of increased risk of blooding complications" is based on evidence or on authors' opinion. Response: Results from both clinical trials with selected patients (Chaitman et al. J Am Coll Cardiol 1989; Aylward et al. Ann Intern Med 1996) and observational studies in real-world populations (Huynh et al. Am Heart J 2004; Brass et al. Stroke 2000; Conrad et al. South Med J 1997; Gurwitz et al. Ann Intern Med 1998; Anderson et al. Am J Cardiol 1991) suggested that higher admission blood pressure level was associated with increased risk of intracerebral hemorrhage in patients with STEMI following thrombolytic therapy. Moreover, significant hypertension on presentation (SBP >180 mmHg or DBP >110 mmHg) was a relative contraindication for thrombolysis in current guideline for management of STEMI (O'Gara et al. Circulation 2013) . Additionally, some studies (Pierre-Louis et al. Am J Ther 2010; Andersen et al. Eur J Cardiovasc Nurs 2005) also revealed that elevated SBP during or after procedure was an independent risk factor for minor bleeding and haematoma in patients underwent PCI and angiography. Therefore, the decision to use those reperfusion strategies such as fibrinolytic therapy for patients with STEMI is predicated on a risk-benefit analysis in clinical practice and those who presented with elevated admission blood pressure level especially excessively elevated SBP such as >180 mmHg were less likely to receive fibrinolytic therapy compared with those with normal admission blood pressure for fear of increased risk of bleeding. To sum up, we sated these contents in our revised version as followings: Some previous studies11-16 have shown elevated admission blood pressure was associated with increased risk of intracerebral hemorrhage in patients with ST-segment elevation myocardial infarction (STEMI) following thrombolytic therapy and elevated blood pressure during or after procedure was an independent risk factor for minor bleeding and haematoma in patients underwent PCI and angiography17, 18. Moreover, significant hypertension on presentation [SBP >180 mmHg or diastolic blood pressure (DBP) >110 mmHg] was a relative contraindication for thrombolysis in current guideline for management of STEMI19. A risk-benefit assessment may compromise the use of reperfusion strategies for those with elevated especially excessively elevated admission blood pressure in daily clinical practice.
The percentage of STEMI patients submitted to reperfusion (thrombolysis or PCI) was low accounting for about 50%, and significantly different in the three subgroups of patients. This finding should be discussed, since it could have been affected the results. Response: Thanks for the reviewer's suggestion. Indeed, the percentage of patients that received reperfusion treatment was low and was significantly different among groups in our study. Patients diagnosed with STEMI within 12 hours after symptoms onset should be given reperfusion treatment according to current guideline. However, this was a national registry study and the medical institutions included in this study covered different levels of medical care (academic and non-academic, general and specialized, urban and rural). Disequilibrium of health care resulted in distinct treatment among those medical institutions. Some hospitals located in rural areas may not be able to perform reperfusion treatment timely and the others located in urban areas may comply with the guideline well, which leaded to a relatively low application of reperfusion in our study. Moreover, the decision to use reperfusion therapy was based on the evaluation that integrated the clinical features at presentation, patient comorbidities, and enablement of medical resource as well as risk-benefit analysis, which disposed STEMI patients with elevated admission SBP to receive less reperfusion treatment. This was a real-world study and was also a reflection of the huge gulf between clinical guidelines and real-world practice. Meanwhile, we also anticipate that studies with standard care would confirm our conclusion. Furthermore, we used Cox regression analysis to eliminate, to some extent, the effect of imbalance of baseline characteristics on the outcome. In the Limitation section of our text, we also addressed this limitation. To sum up these contents, we added comments into the Discussion section in the revised version as followings: In our study, it was found that the percentage of patients that received reperfusion treatment was low and was significantly different among groups. Some possible interpretation should be inferred. This was a multi-center registry study and the medical institutions included in this study covered different levels of medical care (academic and non-academic, general and specialized, urban and rural). Disequilibrium of health care resulted in distinct treatment among those medical institutions, which leaded to a relatively low application of reperfusion in our study. Moreover, the decision to use reperfusion therapy was based on the evaluation that integrated the clinical features at presentation, patient comorbidities, and enablement of medical resource as well as risk-benefit analysis, which disposed STEMI patients with elevated admission SBP to receive less reperfusion treatment. Moreover, the standard medication therapy was inadequate such as relatively lower use of clopidogrel, beta blocker, and statins in our study. This was a real-world study and was also a reflection of the huge gulf between clinical guidelines and real-world practice, and an improved condition was anticipated. Furthermore, we used multivariate Cox regression analysis to eliminate, to some extent, the effect of imbalance of baseline characteristics on the outcome. However, after multivariate adjustment, elevated admission SBP was not associated with increased risk of poor short-term outcome.
Recent investigations addressing the prognostic impact of hypertension in STEMI patients are to be cited and discussed (De Luca G et al J Hypertens 2013 , Cecchi E et al High Blood Press Cardiovasc Prev. 2014 , Lazzeri C et al Heart and Vessels) Response: Thanks for the reviewer's suggestion. We have read carefully the articles abovementioned that systematically investigated the impact of hypertension on the infarction size as well as the short-and long-term outcome in patients with STEMI underwent PCI. In the Discussion section of our revised version, we cited and commented those contents as followings:
However, as far as the impact of hypertension on the short-and long-term outcomes in patients with STEMI is concerned, studies reached inconsistent conclusion. In the thrombolytic era, some studies30, 31 found hypertension adversely affected the short-and long-term outcomes, while others32, 33 found no difference in patients with and without hypertension. In the era of mechanical revascularization, recent several studies evaluated the impact of hypertension on the short-and longterm outcomes in patients with STEMI and reported similar conclusion. In Rembek et al.'s report, 34 no difference was observed in in-hospital mortality between hypertensive and normotensive patients. Parodi et al.35 found the 5-year mortality in patients with and without hypertension was comparable; however, hypertension patients were at higher risk to develop heart failure after STEMI. Lazzeri et al.36 assessed the influence of hypertension on the short-and long-term in 560 STEMI patients submitted to mechanical revascularization and found a history of hypertension had no affect on either short-or long-term mortality. Similar results were also found in Cecchi et al.'s report.37 The reason why hypertension has no significant influence on the outcome in patients with STEMI underwent PCI may be multi-factorial. One possible interpretation is that hypertensive STEMI patients did not show a larger infarct size compared with normotensive patients displayed by De Luca G et al.'s study.38 Another possible explanation was the altered lifestyle and standard anti-hypertensive therapy after STEMI which controlled the main cardiovascular risk factors and resulted in a relatively fair outcome.37 However, although hypertension appears to have no impact on the outcome in STEMI patients underwent PCI, hypertensive patients showed an altered glucose response to stress, as indicated by a higher incidence of acute insulin resistance and higher admission glucose values, which has been demonstrated to be a risk factor for 1-year mortality in STEMI patients underwent PCI with estimated glomerular filtration rate (eGFR) ≥60ml/min/m2.39 Our study also showed patients with elevated admission SBP presented with higher admission blood sugar and after multivariate adjustment, higher admission blood sugar was an independent risk factor for short-term mortality (data not shown).
Reviewer: 2 Reviewer Name Seung-Jung Park, MD, PhD Institution and Country Heart Institute, Asan Medical Center, University of Ulsan, Seoul, Korea Please state any competing interests or state 'None declared': Nothing Huang et al evaluated clinical characteristics and short-term outcome in patients with elevated admission systolic blood pressure after acute ST-elevation Myocardial Infarction (STEMI). They concluded that patients with elevated admission SBP after STEMI have a similar short-term prognosis to those with normal admission SBP. This is an interesting paper. However, I am concerned about the author's conclusions because of the study limitations. 1. Standard of care -Reperfusion therapy: SETMI patients within 12 hours after symptoms onset were included for this study and they should be treated with reperfusion therapy (fibrinolytics or primary PCI). However, ~60% of study patients got reperfusion therapy and the remaining patients departed from standard of care.
-Medications: Only small number of patients took standard medications: clopidogrel (<30%), betablockers (<70%), and statins (~70%) The authors' findings may not be generalized to patients with STEMI undergoing reperfusion therapy and standard medications. Response: We agree with the remark on the standard of care. Indeed, the percentage of patients that received reperfusion treatment was relatively low and the medications including antiplatelet, beta blocker, and statins were inadequate according to the guideline for management of STEMI. However, as is mentioned above, this was a multi-center real-world registry study that covered different levels of medical care (academic and non-academic, general and specialized, urban and rural). Disequilibrium of health care resulted in distinct treatment among those medical institutions. Some hospitals located in rural areas may not be able to perform reperfusion treatment timely and the others located in urban areas may comply with the guideline well, which leaded to a relatively low application of reperfusion in our study. Some medications like clopidogrel may be unavailable in some medical institutions located in rural areas and certain complications such as Killip IV class, hypotension, and severe bradycardia following inferior myocardial infarction as well as the reduced use misjudged by some clinicians may compromise the use of beta blocker, which resulted in a low use of beta blocker. These were the major limitation in our study. We have commented in the Discussion section in the revised version. Meanwhile, due to the major limitation, our findings may not be generalized to patients with STEMI undergoing reperfusion and standard medications, as is remarked by the reviewer. We have stressed this limitation in the Limitation section in our revised version. Meanwhile, we also anticipated more studies in which patients were given standard treatment will confirm our conclusion. The related contents in our revised version are as followings: In our study, it was found that the percentage of patients that received reperfusion treatment was low and was significantly different among groups. Some possible interpretation should be inferred. This was a multi-center registry study and the medical institutions included in this study covered different levels of medical care (academic and non-academic, general and specialized, urban and rural). Disequilibrium of health care resulted in distinct treatment among those medical institutions, which leaded to a relatively low application of reperfusion in our study. Moreover, the decision to use reperfusion therapy was based on the evaluation that integrated the clinical features at presentation, patient comorbidities, and enablement of medical resource as well as risk-benefit analysis, which disposed STEMI patients with elevated admission SBP to receive less reperfusion treatment. Moreover, the standard medication therapy was inadequate such as relatively lower use of clopidogrel, beta blocker, and statins. This was a real-world study and was also a reflection of the huge gulf between clinical guidelines and real-world practice, and an improved condition was anticipated. There are some limitations in our study. First, it is a retrospective observational study and causal relationship can't be inferred. Due to the insufficiency of guideline implementation, our results may not be generalized to patients with STEMI undergoing reperfusion therapy and standard medications. Therefore, prospective studies with standard therapy are needed to confirm our results.
Inclusion criteria:
It is unclear why the authors excluded patients with admission SBP < 100mmHg. Response: We are very sorry to remark the inclusion criteria unclearly. Our study mainly aims to evaluate the impact of elevated admission on the short-term outcome in patients with STEMI, therefore, we divided these patients into groups with normal admission SBP, modestly elevated admission SBP, and excessively elevated admission SBP, and made a comparison of clinical characteristics and outcomes in patients with elevated admission SBP versus normal admission SBP. Those who presented with admission SBP<100 mmHg has been confirmed to at high risk of cardiovascular events according to the TIMI score or GRACE score in which patients with SBP<100 mmHg get 3 points and 53 scores or 58 scores (<80 mmHg). A considerable number of these patients may be complicated by cardiogenic shock. Therefore, these patients had a poor outcomes compared with those with normal or elevated admission SBP. In order to compare the different outcomes between patients with normal and elevated admission SBP, those with admission SBP<100 mmHg were exclude. The similar inclusion criteria were also seen in other study (Jonas et al. Am J Cardiol 1999) . We also remarked the inclusion criteria more clearly in our revised version as followings: In addition, a total of 796 patients with admission SBP <100 mmHg were excluded because they belonged to a well-defined group known to have a poor outcome according to previous studies3, 5, 21 3. Definitions: Bleeding definition is less unclear. The author had better use BARC definition to define bleeding complications. Response: Thanks for the reviewer's suggestion. The lack of a standard bleeding definition and the inability to compare bleeding rates across trials led to the formation of the Bleeding Academic Research Consortium (BARC). The validity of this newly proposed definition has been confirmed by some studies. We use this definition to class the bleeding events in our study in the revised version.
However, the data of bleeding was recorded based on the pre-designed case report form that was not so explicit as in the BARC definition, therefore, we divided our bleeding events into 3 groups according to the BARC definition, that is type 1 and 2, type 3, and type 5, while data of type 4 (CABG related bleeding) was unavailable in our pre-designed case report form. Meanwhile, we added a table in our revised version showing the comparison of bleeding events with BARC definition among groups. Additionally, we also analyzed the risk factors associated with bleeding events with multivariate logistic regression analysis in order to demonstrate whether elevated admission blood pressure was an independent risk factor of bleeding events in our revised version. The related contents in our revised version are as followings: Bleeding was defined according to the Bleeding Academic Research Consortium (BARC) definitions22 as followings: type 1 is in which the patient does not seek treatment; type 2 is in which intervention or admission to hospital occurs; type 3a is overt bleeding plus hemoglobin drop of 3 to less than 5 g/dl or transfusion; type 3b is overt bleeding plus hemoglobin drop of at least 5 g/dl, cardiac tamponade, bleeding requiring surgical intervention or intravenous vasoactive agents; type 3c is intracranial hemorrhage or intraocular bleeding compromising vision; type 4 is coronary artery bypass grafting-related bleeding and type 5 is fatal bleeding. Due to the limitation of data and lack of data about coronary artery bypass grafting-related bleeding, we analyzed the data of type 1 and type 2, type 3, and type 5. Table 3 shows the incidence of 7-and 30-day bleeding events according to the BARC definition stratified by admission SBP. The incidence of type1 and type 2, type 3, as well as type 5 within 7 days were similar among groups (P=0.979). The 30-day values among groups were also comparable (P=0.523). Table 4 displays the factors associated with 30-day bleed events by logistic regression analysis. It was found that advanced age, low weight, thrombolysis, PCI treatment, and aspirin use were independent risk factors predicting short-term bleeding events, while elevated admission SBP was not associated with increased risk of short-term bleeding compared with normal admission SBP (OR=1.108, 95%CI 0.677-1.816, P=0.683 for modestly elevated admission SBP and OR=2.119, 95%CI 0.746-6.013, P=0.158 for excessively elevated admission SBP, respectively). Table 3 4. Lack of data: It is well demonstrated that LV function (ejection fraction) and the extent and severity of residual coronary artery disease are two major determinants of prognosis after STEMI. The authors failed to show two key predictors of prognosis Response: As the reviewer remarked, LVEF and the extend and severity of residual coronary artery disease are two major determinants of prognosis after STEMI, however, due to the retrospective study design, the data of LVEF was obtained from only a proportion of patients. Also, only a proportion of patients received PCI treatment and the data of culprit vessel in the remaining patients were lacking. Indeed, absence of these data in our study was an important limitation and we have stressed in the Limitation section. We also anticipate prospective studies will confirm our conclusion. In our revised version, the related contents are as followings: There are some limitations in our study. First, it is a retrospective observational study and causal relationship can't be inferred. Due to the insufficiency of guideline implementation, our results may not be generalized to patients with STEMI undergoing reperfusion therapy and standard medications. Therefore, prospective studies with standard therapy are needed to confirm our results. Second, data about SBP were collected at admission only, whereas detailed treatment and blood pressure control levels during hospitalization and after discharge that might relate to the prognosis were not available. Third, due to the retrospective study design, other data such as left ventricular mass, left ventricular ejection fraction (LVEF), severity of the residual stenosis of the infarct-related coronary artery, and biomarkers of myocardial necrosis that were valuable parameters for evaluating prognosis were lacking. In addition, the number of patients with excessively elevated admission SBP was relatively small and might limit the statistical power. Finally, the follow-up time in our study was short and a long-term follow-up is required to evaluate the long-term prognostic value of elevated admission SBP in patients with STEMI.
VERSION 2 -REVIEW

REVIEWER
Lazzeri Chiara intensive cardiac care unit heart and vessel deparment Azienda Ospedaliero-Universitaria Careggi Florence Italy REVIEW RETURNED 11-May-2014 -The reviewer completed the checklist but made no further comments.
